Clinical trial
A Phase IIa, Randomized, Double-blind, Dose Comparison, Placebo-controlled, Multi-centre Clinical Trial to Evaluate the Immune Signature of the Treatment With the Imotope IMCY-0098 and Its Effect on the Preservation of Beta-cell Function in Adult Patients With a Recent Onset Type 1 Diabetes
NCT04524949 is registered in ClinicalTrials.gov with Imcyse SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa, Randomized, Double-blind, Dose Comparison, Placebo-controlled, Multi-centre Clinical Trial to Evaluate the Immune Signature of the Treatment With the Imotope IMCY-0098 and Its Effect on the Preservation of Beta-cell Function in Adult Patients With a Recent Onset Type 1 Diabetes
- Lead sponsor
- Imcyse SA
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 29, 2020
- Completion date
- May 29, 2024
- Enrollment
- 110 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.